Calocurb, a natural appetite-control supplement brand, enters UK market

New Zealand brand Calocurb has announced its entry into the UK market. The company positions its natural product as a non-prescription alternative to GLP-1 medications. According to NutraIngredients, practitioners will be the first channel, and distribution will be expanded gradually.

Brand history and US launch

Calocurb was founded in New Zealand in 2017 and launched in the US in 2018. Founder and CEO Sarah Kennedy told NutraIngredients that the industry is gradually moving away from weight-loss messaging towards a broader focus on metabolic health, appetite regulation and body composition. She said UK consumers and practitioners had shown interest for some time, with many seeking the brand out at US conferences.

Kennedy said the US market experience showed steady demand for non-prescription weight management products. The UK strategy, she added, takes local market features into account.

Clinical data

The company cites four human clinical trials. The latest, according to Kennedy, was published in Obesity Pillars this year. In a 24-week randomized, placebo-controlled trial, participants taking Calocurb lost an average of 3.8kg, versus 0.4kg in the placebo group. The trial also reported greater reductions in body fat and visceral fat, with skeletal muscle mass preserved.

Earlier studies cited by the company reported reductions in hunger (30%), food cravings (40%) and calorie intake (18%). These figures come from the brand itself, and the material does not explain how they were measured or how comparable they are.

According to Kennedy, the active ingredient Amarasate activates bitter taste receptors in the gut, stimulating the release of satiety hormones including GLP-1, CCK and PYY. The company says the product is backed by 16 years of research and a $30 million investment.

What comes next

Calocurb plans to first build partnerships with practitioners and share its clinical data, then broaden distribution. Kennedy said the company aims to raise the bar for the whole natural weight management category. Launch timing, pricing, retail channels and the product's regulatory status in the UK were not disclosed.